After spending $87M promoting Lipitor in the U.S. even after its patent expired, Pfizer (PFE) is...


After spending $87M promoting Lipitor in the U.S. even after its patent expired, Pfizer (PFE) is giving up on its former cash cow for good because more generic versions will soon be going on sale. For its next act, PFE is trying to reshape itself into a leaner company, but analysts say it might still be too big for the cost-cutting and launches of new drugs like tofacitinib to have a significant effect.

From other sites
Comments (1)
  • afleischner
    , contributor
    Comments (5) | Send Message
     
    when Pfizer was taken over by the bureacrats it was the beginning of the decline. The current managers don't understand pharmaceutical sciences. The pharmacy schools have watered down the curriculum so that you can't go to grad school directly because the present curriclum has to many holes in it. Things will only get worse.
    9 May 2012, 09:57 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs